A randomized, double-blind, 2-period, crossover study to establish the dose equivalence and direct conversion between immediate release (IR) and extended-release (ER) CG5503 [tapentadol] in subjects with moderate-to-severe, chronic low back pain.

Trial Profile

A randomized, double-blind, 2-period, crossover study to establish the dose equivalence and direct conversion between immediate release (IR) and extended-release (ER) CG5503 [tapentadol] in subjects with moderate-to-severe, chronic low back pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2010

At a glance

  • Drugs Tapentadol (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Feb 2010 According to a media release from Johnson & Johnson, results will be presented at the American Academy of Pain Medicine's 26th annual meeting.
    • 29 Jan 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Planned number of patients changed from 75 to 120 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top